Other languages Rallybio Corporation

Equities

RLYB

US75120L1008

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
1.67 ^USD	+5.03%		+7.05%	-30.13%

May. 15	JPMorgan Downgrades Rallybio to Neutral From Overweight	MT
May. 09	Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Downgrades Rallybio to Neutral From Overweight	May. 15
Rallybio : The Citizens JMP Life Sciences Conference	May. 15
Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates	May. 09
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference	May. 07
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting	Apr. 17
Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting	Apr. 17
Key Stocks to Watch: Recent News, Developments and Market Potential KAVL, INBS, GEVI, VTAK, RLYB	Apr. 15
Top Premarket Decliners	Apr. 12
US Equity Markets Close Mixed After March Producer Price Inflation Data	Apr. 11
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 11
Top Midday Gainers	Apr. 11
Wedbush Lowers Rallybio's PT to $11 From $13 After Private Placement, Adjusts Full-Year 2024 Share Count; Maintains Outperform Rating	Apr. 11
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Another Key Inflation Report	Apr. 11
Top Premarket Gainers	Apr. 11
Rallybio Corporation Announces Collaboration with Johnson & Johnson	Apr. 10
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)	Apr. 10
Rallybio Corporation announced that it has received $6.599999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.	Apr. 09
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting	Apr. 01
HC Wainwright Cuts Rallybio Price Target to $9 From $12, Maintains Buy Rating	Mar. 13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Rallybio Corporation

Equities

RLYB

US75120L1008

Other languages

Filters